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ABSTRACT 
 Hemophilia unfortunately a less attracted disease for researchers compared to other life 
threatening diseases. The prevalence of hemophilia is estimated to be about 1:10,000 birth 
and that of the severe form of the disease to be about 6% per 1,00,000 population. The most 
pathetic part of this disease is that even medical personnel are sometimes not familiar with its 
diagnosis and management. There is obviously a need to establish facilities and treatment 
options that will help the patient with hemophilia to manage their life with ease. As this is a 
genetic disorder no complete cure is possible as of now. The only available treatment option 
is the infusion of factors and some adjuvant therapies depending upon the bleeding conditions 
.The initiative for the development of new dosage forms, new delivery systems of the existing 
therapies or new treatment options has to be driven by pharmacy professionals. This article 
present an overview of hemophilia, in order to drag the attention of medical as well as 
pharmacy professionals for the benefit of millions of hemophilic patients . 
Introduction  
 
Hemophilia is a group of inherited blood disorders in which 
the blood does not clot properly. Hemophilia is the standard 
international spelling, also known as haemophilia in the UK, 
other translations include: hémophilie, hemofilie, hemofili, 
hemofilia, hämophilie, emofilia. We will use the standard 
international spelling for the purpose of this section[1]. 
Bleeding disorders are due to defects in the blood vessels, the 
coagulation mechanism, or the blood platelets[2]. An affected 
individual may bleed spontaneously or for longer than a 
healthy person after injury or surgery. 
The blood coagulation mechanism is a process which 
transforms the blood from a liquid into a solid, and involves 
several different clotting factors. The mechanism generates 
fibrin when it is activated, which together with the platelet 
plug, stops the bleeding. 
When coagulation factors are missing or deficient the blood 
does not clot properly and bleeding continues. 
Patients with Hemophilia A or B have a genetic defect which 
results in a deficiency in one of the blood clotting factors. 
 
Types of Hemophilia / Haemophilia 
Hemophilia A and Hemophilia B[3] 
There are two main types of hemophilia - Hemophilia A (due 
to factor VIII deficiency) and Hemophilia B (due to factor IX 
deficiency). They are clinically almost identical and are 
associated with spontaneous bleeding into joints and muscles 
and internal or external bleeding after injury or surgery. 
After repeated bleeding episodes permanent damage may be 
caused to the joints and muscles that have been affected, 
particularly the ankles, knees and elbows[4]. 
Approximately 1 in 5,000 males is born with Hemophilia A, 
and 1 in 30,000 males is born with Hemophilia B. Hemophilia 
affects people of all races and ethnic origins globally. The 
conditions are both X-linked and virtually all sufferers of 
hemophilia are males. Female carriers may also bleed 
abnormally, because some have low levels of the relevant 
clotting factor. 
People with hemophilia have a genetic mutation in the 
affected gene on the X chromosome, which results in reduced 
production of Factor VIII or IX and creates a bleeding 
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tendency, because coagulation takes much longer than normal, 
thus making the clot weak and unstable[5]. Approximately one 
third of patients with hemophilia have no family history of the 
disease, either because of new genetic mutations, or because 
previous affected generations either had daughters (who were 
carriers) or sons who died in early childhood from hemophilia 
or any other cause or who were not affected[6,7]
 
Acquired hemophilia  
This is very rare. The patient develops the condition during 
his/her lifetime and it does not have a genetic or heritable 
cause. It occurs when the body forms antibodies that attack 
one or more blood clotting factors, (usually factor VIII), thus 
preventing the blood clotting mechanism from working 
properly. Patients may be male or female and the pattern of 
bleeding is rather different from that of classi
the joints being rarely affected. The disorder is particularly 
associated with old age and occasionally complicates 
pregnancy[8]. 
 
Causes Hemophilia[9] 
People with hemophilia are born with it. It is caused by a fault 
in one of the genes that determine how the body makes blood 
clotting factor VIII or IX. These genes are located on the X 
chromosome. 
To understand how hemophilia is inherited, it is important to 
learn about chromosomes. 
Female (X + Xfaulty) is a carrier, but does not have 
hemophilia. The “good” X chromosome allows the production 
of enough clotting factor to prevent serious bleeding 
Male (Y + Xfaulty) will develop hemophilia and can pass it 
on. 
If the father has hemophilia and the mother has no faulty gene 
(is not a carrier):  
Father (Y + Xfaulty). Mother (X + X). 
 et al. / Indian J. Pharm. Biol. Res., 2014; 2(4):68-76 
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cal hemophilia, 
What are chromosomes? Chromosomes are blocks of DNA 
(deoxyribonucleic acid). They contain very detailed and 
specific instructions that determine:
How the cells in a baby's body develop.
What features the baby will have, including, for example, hair 
and eye color. 
Whether the baby is male or female.
In humans there are 23 pairs of chromosomes, including the 
sex chromosome pair.  
There are two types of sex chromosome: 
The X chromosome 
The Y chromosome 
All humans have a pair of sex chromosomes: [10]
Males have an X + Y pair 
Females have an X + X pair
NB  Females do not have any Y chromosomes.
What chromosomes do we inherit from our parents? 
A Male inherits his 
X chromosome from his mother
Y chromosome from his father
A Female inherits 
One X chromosome from her mother
One X chromosome from her father
She does not inherit both X chromosomes from her mother. 
She has no Y chromosomes.
[11,12]How can we calculate the risk of hemophilia in 
offspring? x-linked recessive, carrier mother (Before reading 
on, remember that the faulty gene is never on the Y 
chromosome. If it is present, it will be on the X chromosome.)
 
problems. 
There is no risk of inherited hemophilia in their sons becaus
boys will inherit their X chromosome from the mother, not the 
father (they inherit the father's Y chromosome only, which 
does not have the faulty gene).
All the daughters will be carriers but will not develop 
hemophilia although they will inherit the fat
chromosome, which has the faulty gene. However, their 
maternal X chromosome, which does not have the faulty gene, 
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usually allows the production of enough clotting factor to 
prevent serious bleeding problems. 
If the father does not have hemophilia and the mother has a 
faulty gene:  
Father (Y + X). Mother (X + Xfaulty). 
There is a 50% chance that sons will develop hemophilia 
because:  There is a 50% risk that a son will inherit his 
mother's Xfaulty chromosome, plus his father's Y 
chromosome - he will have hemophilia. There is a 50% chance 
he will inherit his mother's "good" X chromosome, plus his 
father's Y chromosome - he will not have hemophilia. There is 
a 50% chance that daughters will be carriers, (but no chance of 
developing hemophilia), because:  There is a 50% chance she 
will inherit her mother's Xfaulty chromosome, making her a 
carrier. There is a 50% chance she will inherit her mother's 
"good" X chromosome, which would mean she would not be a 
carrier. Approximately one third of patients with hemophilia 
have no family history of the disease, either because of new 
genetic mutations, or because previous affected generations 
either had daughters (who were carriers) or sons who died in 
early childhood from hemophilia or any other cause or who 
were not affected. 
 
Pathophysiology[13-15] 
 
Factor VIII production, processing, and structure 
 
Primary sites of factor VIII (FVIII) production are thought to 
be the liver and the reticuloendothelial system. Liver 
transplantation corrects FVIII deficiency in persons with 
hemophilia, and persons with mild hemophilia with 
progressive liver disease have a rise in FVIII levels, thus 
establishing the liver as the major site of FVIII synthesis. 
FVIII messenger RNA has been detected in the liver, spleen, 
and other tissues.[3] Studies of FVIII production in transfected 
cell lines have shown that following synthesis, FVIII moves to 
the lumen of the endoplasmic reticulum, where it is bound to 
several proteins that regulate secretion, particularly 
immunoglobulin binding protein, from which it has to 
dissociate in an energy-dependent process. 
Cleavage of FVIII's signal peptide and the addition of 
oligosaccharides also occur in the endoplasmic reticulum. The 
chaperone proteins, calnexin and calreticulin, enhance both 
FVIII secretion and degradation. 
A part of the factor FVIII protein in the endoplasmic reticulum 
is degraded within the cell. The other part enters the Golgi 
apparatus, where several changes occur to produce the heavy 
and light chains and to modify the carbohydrates. The addition 
of sulfates to tyrosine residues of the heavy and light chains is 
necessary for full procoagulant activity, with the sulfated 
region playing a role in thrombin interaction. This 
posttranslational sulfation of tyrosine residues impacts the 
procoagulant activity of factor VIII and its interaction with 
von Willebrand factor (vWF). 
 
vonWillebrand factor[16] 
FVIII circulates in plasma in a noncovalently bound complex 
with vWF, which plays significant roles in the function, 
production, stabilization, conformation, and immunogenicity 
of FVIII.[4] VWF has been termed FVIII-related antigen 
(FVIII-R); related terminology for FVIII is FVIII-coagulant 
(FVIII-C). 
VWF appears to promote assembly of the heavy and light 
chains of FVIII and more efficient secretion of FVIII from the 
endoplasmic reticulum. It also directs FVIII into the Weibel-
Palade bodies, which are the intracellular storage sites for 
vWF. 
In plasma, vWF stabilizes FVIII and protects it from 
degradation. In the presence of normal vWF protein, the half-
life of FVIII is approximately 12 hours, whereas in the 
absence of vWF, the half-life of FVIII-C is reduced to 2 
hours.[5, 6, 7] 
 
The clotting cascade 
 
[17]The role of the coagulation system is to produce a stable 
fibrin clot at sites of injury. The clotting mechanism has 2 
pathways: intrinsic and extrinsic. See the image below. 
 
Coagulation pathway 
The intrinsic system is initiated when factor XII is activated 
by contact with damaged endothelium.[18] The activation of 
factor XII can also initiate the extrinsic pathway, fibrinolysis, 
kinin generation, and complement activation. 
 
In conjunction with high-molecular-weight kininogen 
(HMWK), factor XIIa converts prekallikrein (PK) to kallikrein 
and activates factor XI. Activated factor XI, in turn, activates 
factor IX in a calcium-dependent reaction. Factor IXa can bind 
phospholipids. Then, factor X is activated on the cell surface; 
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activation of factor X involves a complex (tenase complex) of 
factor IXa, thrombin-activated FVIII, calcium ions, and 
phospholipid. 
In the extrinsic system, [19]. The conversion of factor X to 
factor Xa involves tissue factor (TF), or thromboplastin; factor 
VII; and calcium ions. TF is released from the damaged cells 
and is thought to be a lipoprotein complex that acts as a cell 
surface receptor for factor VII, with its resultant activation. TF 
also adsorbs factor X to enhance the reaction between factor 
VIIa, factor X, and calcium ions. Factor IXa and factor XII 
fragments can also activate factor VII. 
In the common pathway, factor Xa (generated through the 
intrinsic or extrinsic pathways) forms a prothrombinase 
complex with phospholipids, calcium ions, and thrombin-
activated factor Va. The complex cleaves prothrombin into 
thrombin andprothrombin fragments 1 and 2. 
Thrombin converts fibrinogen into fibrin and activates FVIII, 
factor V, and factor XIII. Fibrinopeptides A and B, the results 
of the cleavage of peptides A and B by thrombin, cause fibrin 
monomers to form and then polymerize into a meshwork of 
fibrin; the resultant clot is stabilized by factor XIIIa and the 
cross-linking of adjacent fibrin strands. 
Because of the complex interactions of the intrinsic and 
extrinsic pathways (factor IXa activates factor VII), the 
existence of only one in vivo pathway with different 
mechanisms of activation has been suggetdSee the image 
below.
 
 
The hemostatic pathway. APC = activated protein C  
The hemostatic pathway. APC = activated protein C (APC); 
AT-III = antithrombin III; FDP = fibrin degradation products; 
HC-II = heparin cofactor II; HMWK = high-molecular-weight 
kininogen; PAI = plasminogen activator inhibitor; sc-uPA = 
single-chain urokinase plasminogen activator; tc-uPA = two-
chain urokinase plasminogen activator; TFPI = tissue factor 
pathway inhibitor; tPA = tissue plasminogen activator 
[20]FVIII and factor IX circulate in an inactive form. When 
activated, these 2 factors cooperate to cleave and activate 
factor X, a key enzyme that controls the conversion of 
fibrinogen to fibrin. Therefore, the lack of FVIII may 
significantly alter clot formation and, as a consequence, result 
in clinical bleeding. 
 
Hemophilia Symptoms and Diagnosis[21,22] 
Hemophilia symptoms vary, depending on the degree of blood 
clotting factor (coagulation factor) deficiency and they also 
depend on the nature of any injury. 
Three levels of hemophilia are recognized, according to the 
level of clotting factor amounts in the blood. These are often 
expressed as percentages of normal: 
Above 5% - mild hemophilia 
1% to 5% - moderate hemophilia 
Less than 1% - severe hemophilia 
 
Mild hemophilia 
People with inherited mild hemophilia may not have any 
symptoms until an event occurs which wounds the skin or 
tissue, such as a dental procedure or surgery, and results in 
prolonged bleeding. In societies where male circumcision is 
carried out soon after birth, mild hemophilia will be detected 
earlier. Joint bleeding is uncommon. 
 
Moderate hemophilia 
Those with inherited moderate hemophilia will be noticeable 
early on. The child will bruise easily and may also experience 
internal bleeding symptoms, especially around the joints, and 
after a blow or a fall. Bleeding that occurs inside a joint is 
usually referred to as a joint bleed. 
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Symptoms of a joint bleed 
Tingling sensation in the joint, Pain in the joint, Irritation in 
the joint, If left untreated, the patient may eventually 
experience: 
More severe pain in the joint, Joint stiffness, The affected area 
becomes swollen, tender and hot Joint bleeds most commonly 
affect the: Ankles, Knees, Elbows and may less commonly 
affect the shoulders, hips or other joints. 
Any surgical intervention, circumcision, dental procedure or 
injury will result in prolonged bleeding in a person with 
hemophilia. 
Symptoms are similar to those found in moderate hemophilia, 
but occur more frequently and are usually more severe. 
 
A child with severe hemophilia will often bleed for no 
apparent reason, often referred to as spontaneous bleeding. 
Most commonly, in early childhood from about 18 months of 
age, the nose or mouth start to bleed or apparently 
spontaneous bruises appear, particularly on the legs. Parents 
are sometimes suspected of causing non-accidental injury 
(deliberate harm) to their children. 
Symptoms of hemophilia type bleeding may 
include:[23,34,25] 
Several large or deep bruises, Joint pain or swelling, 
Unexplained bleeding or bruising, Blood in feces (stools), 
Blood in urine, Unexplained nosebleeds, Unexplained gum 
bleeding, Tightness in the joints 
 
Intracranial hemorrhage (bleeding inside the skull) 
About 1 in every 30 patients with hemophilia will have 
intracranial hemorrhage at least once during their lives. This 
should be treated as a medical emergency. Spontaneous 
intracranial hemorrhage is rare and in many cases bleeding 
inside the skull will be the result of a blow to the head. 
 
Symptoms of intracranial hemorrhage include: 
A bad headache, Vomiting, Confusion, Fitting (Convulsion), 
Loss of balance, Slurred speech, or other speaking difficulties, 
Stiff neck, Vision problems, Loss of coordination, Some of the 
facial muscles do not work (sometimes all of them) 
 
How is hemophilia diagnosed? 
Prenatal testing - if a pregnant woman has a history of 
hemophilia, a hemophilia gene test can be done during 
pregnancy. A sample of placenta is removed from the uterus 
and tested. This test is known as a CVS (chorionic villus 
sampling) test. 
Blood test - if a doctor suspects a child may have hemophilia a 
blood test can determine whether the patient has hemophilia A 
or B, and how severe it is. Blood tests can be performed from 
the time of birth onwards. 
 
Treatment for Hemophilia / Haemophilia[26,27] 
Up to a few decades ago a considerable proportion of patients 
with hemophilia died prematurely because of hemophilia. 
Tragically, many deaths were the result of childhood injury or 
surgery. Over the last forty years treatment has advanced so 
much that the vast majority of patients today are expected to 
live long and active lives. 
The main breakthrough in treatment occurred when 
coagulation factor deficiencies linked to hemophilia could be 
identified and then replaced, using products derived from 
human blood. 
In the past patients used to receive whole blood or plasma 
infusions to control episodes of bleeding. Even though this 
helped, levels of clotting factors, especially factors VIII and 
IX, never reached the levels required for really effective blood 
coagulation, nor could these levels be sustained - in other 
words, serious bleeding was only partly treated. 
Cryoprecipitate, made through the cold precipitation of frozen 
plasma from1965 onwards, was the first really effective 
treatment for hemophilia A. Freeze-dried concentrates made 
from human plasma containing the right levels of Factors VIII 
and IX became available in the late 1960s and early 1970s. 
Being able to keep the treatment at home and use it as required 
meant that patients could travel, leave the home, go to work, 
and enjoy a level of independence. However, a large number 
of patients subsequently became infected with blood-borne 
pathogens, such as hepatitis B, hepatitis C and HIV. 
From the mid 1980s rigorous donor selection and viral 
inactivation procedures reduced the risk of blood-borne viral 
transmission to nearly zero. During the 1990s it became 
possible to prepare synthetic (recombinant) factors, using 
specially prepared mammalian cells and these recombinant 
concentrates are now widely used. 
Hemophilia treatment will mainly depend on its severity and 
for patients with Hemophilia A or B involves clotting factor 
replacement therapy. There are two approaches: 
• On demand - giving treatment to stop prolonged 
bleeding when it occurs. This is more common in the 
management of patients with mild hemophilia. 
• Preventative treatment (prophylaxis) - medication to 
prevent bleeding episodes, and subsequent 
complications, such as joint and/or muscle damage. 
More commonly used for patients with moderate or 
severe hemophilia. 
 
Clotting factor concentrates [28] 
Clotting factor concentrates can be made in two different 
ways: 
Plasma-derived clotting factors - prepared from the plasma of 
donated human blood. 
Recombinant clotting factors - the first generation of 
recombinant products use animal products in the culture 
medium and had human albumin (a human blood product) 
added as a stabiliser. Second generation products use animal-
derived materials in the culture medium but do not have added 
albumin and instead use sucrose or other non-human derived 
material as a stabiliser. Third generation clotting factors have 
no albumin present at any stage of their preparation. Mouse 
monoclonal antibodies have been routinely used in the 
purification of coagulation factors for many years but a 
recently licensed recombinant factor VIII employs a synthetic 
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ligand for this step. [29]This has resulted in the production of 
the first factor VIII concentrate to be free of all exogenous 
human and animal protein, a goal which was reached for 
hemophilia B when the first recombinant factor IX was 
licensed in 1997. 
 
Desmopressin (DDAVP)(for mild hemophilia A)[30] 
This medication is a synthetic hormone which encourages the 
body to produce more of its own Factor VIII. It is unsuitable 
for patients with hemophilia B and those with severe 
hemophilia A. In patients with milder forms of hemophilia A, 
factor VIII replacement therapy may be necessary, especially 
for severe bleeds, or after serious injury or major surgery. 
 
RICE (Rest, Ice, Compression, Elevation)[31,32,33] 
RICE is a treatment many health care professionals 
recommend for joint bleeds. It also reduces swelling and tissue 
damage when used together with clotting factor concentrates. 
Administering clotting factor concentrates 
The medication is injected into a vein - generally in the back 
of the hand or at the crook of the elbow. Initial treatments are 
usually administered by a doctor or nurse at a hospital or 
clinic. Most adults can learn how to do this themselves, which 
means they can stop bleeding rapidly and effectively wherever 
they are. 
If the patient is a child the parents or caregivers 
(UK/Ireland/Australia: carers) can learn how to administer 
treatment. The majority of very young patients can receive 
most of their treatment at home. 
If a patient is finding it hard to access a suitable vein, or if 
intensive treatment is required, a port-a-cath, or an external 
catheter called a Broviac or Hickman line can be placed 
surgically into a vein, allowing factor replacement therapies to 
be given, and blood to be drawn easily for routine emergency 
tests. The use of such catheters can be complicated by 
infection and blockage and they have to be used with great 
care. 
 
Treating bleeds[34] 
Bleeding episodes (bleeds) are an inevitable complication for 
patients with hemophilia A and B, even for patients with mild 
forms. As the underlying problem is one of prolonged 
bleeding, rather than rapid bleeding, they often appear not to 
be medical emergencies. 
If a person with hemophilia experiences any of the 
following he should seek immediate skilled medical 
help:[35-37] 
There is an injury to the neck, mouth, tongue, face or eye. 
There is a severe blow to the head. Bleeding is heavy or 
persistent. There is severe pain or swelling in any part of the 
body. An open wound requires stitching. 
Most other bleeds, such as joint/muscle bleeds, small injuries 
and cuts that do not require stitches, and nosebleeds are 
generally treated at home, but patients should always seek the 
advice of a healthcare professional when in doubt. Any 
treatment will be more effective if it is started early. 
 
 
Storing treatment[38,39] 
Factor concentrates should usually be stored in a refrigerator 
but are stable at room temperature for quite long periods. They 
should not be frozen as this may damage the vials or syringes. 
Some may be taken out for travel but should ideally be kept in 
a cool bag. Read instructions on product storage. If you are 
unsure, check with a health care professional or qualified 
pharmacist. 
 
Inhibitors[40-44] 
Approximately 30% of people with severe hemophilia A 
develop antibodies to transfused factor VIII, usually shortly 
after their first few treatments. These antibodies (also called 
inhibitors) prevent the factor VIIII treatment working 
properly. It is often the case that, after a while, the inhibitors 
disappear and only about 10% or less of people with severe 
hemophilia A will suffer from long term inhibitors. In recent 
years it has become possible to prevent inhibitors becoming 
persistent through immune tolerance induction therapy. Where 
inhibitors do not respond to this approach alternative 
treatments are available. 
Inhibitors rarely develop in mild hemophilia A or in 
hemophilia B of any severity. 
 
Prevention[45-50] 
The transmittance of the hemophilia to the next generation can 
be prevented by the following methods. 
1)Prenatal intrauterine diagnosis with termination of 
pregnancy as an option 
2)Pre implantation genetic diagnostic testing (PGD) 
3)IVF with egg/sperm donation 
therapies under investigation 
 
Longer acting factor concentrates[51,52,53] 
A longer-acting factor VIII concentrate has recently been 
approved by the FDA for clinical trials. The hope is that one 
infusion a week rather than three to four infusions a week will 
provide prophylaxis against spontaneous bleeding.  
A preparation in which recombinant factor IX is fused to a 
portion of the immunoglobulin Fc protein shows prolonged 
survival and efficacy in animal models.29 Clinical trials are 
planned but have not yet been initiated. 
 
Gene therapy 
Scientists at The Children's Hospital of Philadelphia 
conducted an experimental protocol involving dogs with a 
genetic defect predisposing them to develop hemophilia B. 
Functional genes capable of producing the clotting Factor IX 
were attached to an adeno-associated virus vector and injected 
into the leg muscles of the animals. The theory was that the 
genetically modified virus would carry the missing gene to 
muscle cells, which in turn would take up the gene and begin 
producing the clotting factor and releasing it into the blood 
stream. 
Sustained therapeutic expression of factors VIII and IX has 
been achieved in preclinical studies using a wide range of 
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gene transfer technologies targeted at different tissues. This 
achievement has led to six different phase I/II clinical trials 
that resulted in limited efficacy but minimal toxicity. 
Recombinant adeno-associated viral vectors appear most 
promising for hemophilia gene therapy. 
Attempts are being made to learn more about the immunology 
of inhibitors and ways to prevent them or improve the success 
rate of immune tolerance. 
 
Future[54,55] 
Gene therapy, oral delivery of factor concentrates, long acting 
infusions, controlled release implants, prolonged release of 
other adjuvant therapy drugs are the areas to be concentrated 
for making the life of hemophilic patients easier. A schematic 
representation is given in the Figure 7. 
Conclusion 
Hemophilia is a bleeding disorder, very hard to live with. As 
the number of patients reported with hemophilia is 
comparatively less than other major diseases like cancer, 
cardiac diseases, and diabetics it seems to be less concentrated 
area by researchers. As technologies develop, the days are not 
far away when hemophilia is treated with ease and even 
complete cure possible. 
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